Chikungunya Market Report 2026

The chikungunya market size has grown strongly in recent years. It will grow from $0.65 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing incidence of mosquito-borne viral infections, expansion of endemic regions due to climate variability, limited availability of approved vaccines, reliance on symptomatic treatment approaches, public health monitoring initiatives.

The chikungunya market size is expected to see strong growth in the next few years. It will grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing investments in vaccine research, rising focus on preventive healthcare, expansion of vector control programs, growing demand for rapid diagnostic solutions, increased global health funding for emerging diseases. Major trends in the forecast period include increasing development of chikungunya vaccines, rising adoption of antiviral treatment protocols, growing focus on early disease diagnosis, expansion of supportive care solutions, enhanced surveillance of mosquito-borne diseases.

The increasing prevalence of mosquito-borne diseases is anticipated to drive the growth of the chikungunya market in the coming years. Mosquito-borne diseases, including chikungunya, dengue, and the Zika virus, are transmitted to humans through infected Aedes mosquitoes and represent major global public health concerns. The growing worldwide incidence of mosquito-borne illnesses is attributed to factors such as climate change, rapid urbanization, deforestation, the presence of stagnant water, insufficient vector control programs, rising international travel, and increasing insecticide resistance. Chikungunya treatment supports patients affected by mosquito-borne diseases by relieving symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, lowering the risk of complications, and supporting recovery through hydration, pain relief, and supportive care. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government agency, reported dengue cases among returning travelers in England, Wales, and Northern Ireland increased to 473 between January and June 2024, representing a 201% rise compared to 157 cases during the same period in 2023. Therefore, the rising global incidence of mosquito-borne diseases is fueling the growth of the chikungunya market.

Major companies operating in the chikungunya market are concentrating on the development of innovative vaccines to strengthen immunity, prevent outbreaks, and address the expanding global health burden associated with chikungunya virus infections. A live attenuated chikungunya vaccine uses a weakened form of the virus to trigger an immune response without causing illness, offering long-lasting protection. For instance, in November 2023, Valneva SE, a France-based biotechnology company, announced the approval of IXCHIQ, a live attenuated chikungunya vaccine, by the U.S. Food and Drug Administration (FDA). This approval was granted under the accelerated approval pathway based on anti-CHIKV neutralizing antibody titers, with continued approval dependent on confirmation of clinical benefit in follow-up studies. Valneva also received a Priority Review Voucher (PRV) from the FDA, which it plans to monetize to support its research and development initiatives. Ixchiq is administered as a single intramuscular injection and contains a live, weakened chikungunya virus, which may result in mild symptoms similar to those of the disease in some recipients.

In February 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired travel vaccine assets from Emergent BioSolutions Inc. for $380 million. Through this acquisition, Bavarian Nordic A/S aims to strengthen its position in the travel vaccines segment by adding marketed products such as Vivotif for typhoid fever prevention and Vaxchora for cholera, along with a phase 3 vaccine candidate for the prevention of chikungunya virus infection. Emergent BioSolutions Inc. is a US-based life sciences company that develops and offers chikungunya vaccines.

Major companies operating in the chikungunya market are F Hoffmann‑La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, Medigen Vaccine Biologics Corp.

North America was the largest region in the chikungunya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chikungunya market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chikungunya market by increasing costs of imported pharmaceutical raw materials, diagnostic reagents, laboratory equipment, and vaccine development inputs. Healthcare systems and research institutions in Asia-Pacific, Latin America, and Africa are most affected due to reliance on imported medical supplies, while North America and Europe face higher R&D and manufacturing expenses. These tariffs are raising treatment and diagnostic costs and slowing large-scale vaccine deployment. However, they are also encouraging domestic pharmaceutical production, regional research collaborations, and localized manufacturing of diagnostics and therapeutics.

The chikungunya market research report is one of a series of new reports that provides chikungunya market statistics, including chikungunya industry global market size, regional shares, competitors with a chikungunya market share, detailed chikungunya market segments, market trends and opportunities, and any further data you may need to thrive in the chikungunya industry. This chikungunya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus and is primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The infection typically leads to symptoms such as fever, joint pain, headache, rash, and muscle pain, which can significantly affect the quality of life of those infected.

The main product types for chikungunya include antiviral drugs, herbal and complementary treatments, supportive care, and vaccines. Antiviral drugs are medications developed to prevent or manage viral infections by inhibiting viral replication within the body. These products are available in various forms, including liquid, powder, and solid formulations. They are used across different stages of the disease, such as the acute, chronic, and post-infection phases. Distribution channels include hospital pharmacies, online pharmacies, retail pharmacies, and supermarkets, and the products are utilized by end users such as caregivers, healthcare professionals, and patients.

The chikungunya market consists of revenues earned by entities by providing services such as vaccination services, diagnostic testing services, and consultation and medical care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chikungunya market also includes sales of vaccines, diagnostic kits, supportive therapies, and diagnostic equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.